Erika P. Hamilton, MD, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer.
Erika P. Hamilton , MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the current treatment paradigm, and upcoming treatments, for HER2-positive breast cancer. She cites the approval of drugs like pertuzumab and T-DM1 over the years as a step in the right direction for treatment of HER2-positive breast cancer, and goes on to say that oncologists have more of an option in treatment now than ever before.
Hamilton says the biggest challenge oncologists face now is figuring out where to place these drugs in the treatment paradigm. She says as T-DM1 and pertuzumab are used more in the neoadjuvant or adjuvant space, the metastatic sequence may be up in the air more.